ENCORE-MEDIA-GROUP
The IoT Tech Expo , Europe’s leading Internet of Things conference and exhibition welcomes Samsung , Vodafone and Ubuntu on board as platinum sponsors for their upcoming event in Berlin , Germany on the 13-14th June. The two day event will cover a range of industries including manufacturing, healthcare, logistics, transport, government, energy and automotive.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160420005975/en/
Over the 2 days there will be 5 dedicated conference tracks :
Topics include: connected car, smart home, customer experience, smart energy, connected home and monetisation
Speakers from: Tado, Shazam, Deutsche Telekom, Dixons Carphone, Ford, Honda and Jaguar Land Rover
Topics include: smart logistics, M2M, fleet management, digitalisation, smart manufacturing, predictive maintenance and telematics
Speakers from: DHL, Sandvik, Volvo, Konecranes, GE, Statoil, Postnord and TVH
Topics include: smart transportation, urban travel, carbon neutral, smart grids, sustainable cities, energy and big data
Speakers from: Continental, E.ON, City of Nice, City of Copenhagen, Bristol Is Open and GE
Topics include: data analytics, mass data collection, privacy challenges, big data modelling, and cyber security
Speakers from: Lufthansa Systems, European Parliament, Swiss Re, Orange and Konecranes
Topics include: robotics, development, connectivity, standards, investment, start-ups, wearables, AR, VR, future fashion, funding and healthcare
Speakers from: Husqvarna Group, Ubuntu, ETH Zurich, IDA Ireland, W3C, TUV, Samsung and Startupbootcamp
View the full speaker line-up, conference agendas and register your pass here: www.iottechexpo.com/germany
Super early bird prices end Friday 29th April so register now to save up to €295 on your delegate pass!
To learn more about the IoT Tech Expo and register your pass, visit the corresponding sites:
• IoT Tech Expo Central Europe : 13-14th June, Berlin Congress Center bcc, Germany
• IoT Tech Expo North America : 20-21st October, Santa Clara Convention Center, San Francisco, CA
• IoT Tech Expo Global : 23-24th January 2017, Olympia, London
For speaking, sponsorship and exhibitor enquiries please contact the team at enquiries@iottechexpo.com or call on +44 (0) 117 980 9023.
NOTES FOR EDITORS
About IoT Tech Expo
The IoT Tech Expo World Series (www.iottechexpo.com ) hosts top level content and discussion, introducing and exploring the latest innovations in the Internet of Things arena. It brings together key industries including Manufacturing, Transport, Health, Logistics, Government, Energy and Automotive.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160420005975/en/
Contact:
IoT Tech Expo
Sarah Wheeler
Events Marketing & Conference
Executive
sarah@iottechexpo.com
+44
(0) 117 980 9023
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 00:45:00 CEST | Press release
POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously treated with systemic chemotherapy The trial met its primary endpoint; treatment with retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) resulted in clinically meaningful improvements in progression-free survival and overall survival In May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz® (retifanlimab-dlwr) in combination with carboplatin and paclitaxel and as a single agent for the treatment of advanced SCAC; submissions to other global regulatory agencies are also under review Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-base
Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 21:30:00 CEST | Press release
Progress in natural refrigerants, water efficiency and circular economy underscores Güntner’s global impact Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal,
Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 20:45:00 CEST | Press release
Windsurf launches a GPU cluster in Germany, delivering 50% faster performance and secure access to European enterprises. Data residency ensures enterprise repositories stay within the EU, meeting stringent security requirements. Windsurf already supports 100+ European enterprise customers, highlighting strong demand for AI-powered development tools across EMEA. Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of
Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 19:00:00 CEST | Press release
New SDK Integration Simplifies Monetization for Defold Developers Publishing on CrazyGames Ahead of Global Game Jam Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization jou
Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies12.6.2025 17:00:00 CEST | Press release
The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Garnett’s research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom